Vor Biopharma Inc
VOR7.950USD
-0.010-0.13%
Close 11/26, 16:00（ET）Quotes delayed by 15 min
71.76MMarket Cap
LossP/E TTM
More Details of Vor Biopharma Inc Company
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.
Vor Biopharma Inc Info
Ticker SymbolVOR
Company nameVor Biopharma Inc
IPO dateFeb 05, 2021
CEODr. Jean-Paul Kress, M.D.
Number of employees159
Security typeOrdinary Share
Fiscal year-endFeb 05
Address100 Cambridgepark Drive
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02140
Phone16176556580
Websitehttps://www.vorbio.com/
Ticker SymbolVOR
IPO dateFeb 05, 2021
CEODr. Jean-Paul Kress, M.D.
Company Executives of Vor Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Sandesh (Sandy) Mahatme
Mr. Sandesh (Sandy) Mahatme
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
13.88M
--
Dr. Qing Zuraw
Dr. Qing Zuraw
Chief Development Officer
Chief Development Officer
937.08K
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Independent Director
Independent Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Sarah Reed
Ms. Sarah Reed
Independent Director
Independent Director
--
--
Mr. Dallan Murray
Mr. Dallan Murray
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sandesh (Sandy) Mahatme
Mr. Sandesh (Sandy) Mahatme
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
13.88M
--
Dr. Qing Zuraw
Dr. Qing Zuraw
Chief Development Officer
Chief Development Officer
937.08K
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Independent Director
Independent Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Nov 20
Updated: Thu, Nov 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
14.40%
Paradigm BioCapital Advisors LP
10.75%
Reprogrammed Interchange LLC
7.17%
VR Adviser, LLC
3.07%
Forbion Capital Partners
2.33%
Other
62.28%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
14.40%
Paradigm BioCapital Advisors LP
10.75%
Reprogrammed Interchange LLC
7.17%
VR Adviser, LLC
3.07%
Forbion Capital Partners
2.33%
Other
62.28%
Shareholder Types
Shareholders
Proportion
Venture Capital
20.14%
Hedge Fund
12.46%
Corporation
7.27%
Investment Advisor
2.96%
Investment Advisor/Hedge Fund
0.32%
Research Firm
0.28%
Bank and Trust
0.18%
Individual Investor
0.14%
Other
56.26%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
155
2.91M
42.56%
-894.32K
2025Q2
165
100.29M
80.27%
+23.22M
2025Q1
174
100.82M
80.73%
+21.38M
2024Q4
172
101.57M
81.78%
+39.14M
2024Q3
175
49.60M
72.03%
-12.93M
2024Q2
174
56.25M
82.04%
-8.25M
2024Q1
168
60.63M
88.57%
-4.75M
2023Q4
163
60.90M
89.54%
-3.77M
2023Q3
164
61.10M
90.20%
-4.10M
2023Q2
166
61.68M
92.10%
-1.24M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
1.98M
28.98%
-1.00
-0.00%
Sep 19, 2025
Reprogrammed Interchange LLC
1.64M
23.96%
-205.17K
-11.12%
Sep 16, 2025
VR Adviser, LLC
25.00K
0.37%
+25.00K
--
Sep 18, 2025
Fidelity Management & Research Company LLC
100.79K
1.47%
-216.12K
-68.20%
Jun 30, 2025
The Vanguard Group, Inc.
95.78K
1.4%
-1.23K
-1.27%
Jun 30, 2025
Johnson & Johnson Innovation-JJDC, Inc.
53.73K
0.79%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 Covered Call ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
DFA Dimensional US Core Equity Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
ProShares UltraPro Russell2000
0%
View more
iShares Russell 2000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Vor Biopharma Inc?
The top five shareholders of Vor Biopharma Inc are:
RA Capital Management, LP holds 1.98M shares, accounting for 28.98% of the total shares.
Reprogrammed Interchange LLC holds 1.64M shares, accounting for 23.96% of the total shares.
VR Adviser, LLC holds 25.00K shares, accounting for 0.37% of the total shares.
Fidelity Management & Research Company LLC holds 100.79K shares, accounting for 1.47% of the total shares.
The Vanguard Group, Inc. holds 95.78K shares, accounting for 1.40% of the total shares.
RA Capital Management, LP holds 1.98M shares, accounting for 28.98% of the total shares.
Reprogrammed Interchange LLC holds 1.64M shares, accounting for 23.96% of the total shares.
VR Adviser, LLC holds 25.00K shares, accounting for 0.37% of the total shares.
Fidelity Management & Research Company LLC holds 100.79K shares, accounting for 1.47% of the total shares.
The Vanguard Group, Inc. holds 95.78K shares, accounting for 1.40% of the total shares.
What are the top three shareholder types of Vor Biopharma Inc?
The top three shareholder types of Vor Biopharma Inc are:
RA Capital Management, LP
Paradigm BioCapital Advisors LP
Reprogrammed Interchange LLC
RA Capital Management, LP
Paradigm BioCapital Advisors LP
Reprogrammed Interchange LLC
How many institutions hold shares of Vor Biopharma Inc (VOR)?
As of 2025Q3, 155 institutions hold shares of Vor Biopharma Inc, with a combined market value of approximately 2.91M, accounting for 42.56% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -37.71%.
What is the biggest source of revenue for Vor Biopharma Inc?
In --, the -- business generated the highest revenue for Vor Biopharma Inc, amounting to -- and accounting for --% of total revenue.
